State Street Corp Increases Position in Danaher Corporation $DHR

State Street Corp raised its holdings in shares of Danaher Corporation (NYSE:DHR) by 1.7% in the 4th quarter, Holdings Channel reports. The institutional investor owned 27,681,334 shares of the conglomerate’s stock after purchasing an additional 472,608 shares during the quarter. State Street Corp’s holdings in Danaher were worth $6,345,529,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Elevated Capital Advisors LLC bought a new stake in shares of Danaher during the fourth quarter valued at approximately $26,000. Hilton Head Capital Partners LLC bought a new stake in shares of Danaher during the fourth quarter valued at approximately $27,000. Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Danaher by 71.6% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 53 shares in the last quarter. JPL Wealth Management LLC bought a new stake in shares of Danaher during the third quarter valued at approximately $25,000. Finally, WFA of San Diego LLC bought a new stake in shares of Danaher during the second quarter valued at approximately $26,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Danaher Stock Performance

Shares of NYSE:DHR opened at $179.95 on Friday. The company has a market capitalization of $127.37 billion, a price-to-earnings ratio of 34.81, a price-to-earnings-growth ratio of 2.41 and a beta of 0.81. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a quick ratio of 1.52, a current ratio of 1.87 and a debt-to-equity ratio of 0.33. The firm has a 50 day moving average of $180.93 and a 200 day moving average of $204.78.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, April 20th. The conglomerate reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.89% and a return on equity of 10.91%. Danaher’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.88 earnings per share. On average, sell-side analysts predict that Danaher Corporation will post 8.45 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a yield of 0.9%. Danaher’s payout ratio is 30.95%.

Analyst Ratings Changes

DHR has been the subject of several research analyst reports. Piper Sandler initiated coverage on shares of Danaher in a research note on Thursday. They set a “neutral” rating and a $200.00 price target for the company. Morgan Stanley decreased their price target on shares of Danaher from $270.00 to $255.00 and set an “overweight” rating for the company in a research note on Wednesday, April 22nd. Citigroup initiated coverage on shares of Danaher in a research note on Tuesday, May 26th. They set a “buy” rating and a $230.00 price target for the company. UBS Group decreased their price target on shares of Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Finally, Wells Fargo & Company decreased their price target on shares of Danaher from $240.00 to $212.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $233.61.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.